IIC1Diprenorphine, a weak partial opiate ag onist, and positron emission tomography were used to obtain noninvasive regional estimates of opiate receptor concentration (Bmax) and affinity (Kd) in human brain. Different compartmental models and fitting strategies were compared statistically to establish the most reliable method of parameter estimation. Paired studies were per formed in six normal subjects using high (769-5,920 Ci/mmol) and low (27-80 Ci/mmol) specific activity (SA) 204 ratio varied from 1.0 ± 0.2 (occipital cortex) to 8.6 ± 1.6 (thalamus). Nonlinear differential equations were used to describe the low SA (high receptor occupancy) kinetics and the curve fits provided the kOlfz product. The mea sured free fraction of [IICldiprenorphine in plasma (fl) was 0.30 ± 0.03, the average K/kz ratio from the two naloxone studies was 1.1 ± 0.2, and the calculated free fraction of [IICldiprenorphine in the brain (fz) was 0.3.
p ICldiprenorphine. Two subjects were studied a third time using high SA [IICldiprenorphine after a pretreat ment with 1-1.5 mg/kg of the opiate antagonist naloxone.
After the plasma radioactivity was corrected for metabo lites, the brain data were analyzed using a three compartment model and nonlinear least-squares curve fit ting. Linear differential equations were used to describe the high SA (low receptor occupancy) kinetics. The k31k4
Opiate receptors mediate the diverse central ef fe cts of the endogenous opioid peptides and exog enous opioid substances, including alteration of mood, decreased respiration, reduction of seizure activity, and changes in eating and drinking behav ior. Changes in the number or affinity of specific neuroreceptors, including opiate receptors , in a va-riety of neurological and psychiatric disorders have been demonstrated by in vitro methods. The char acterization of neuroreceptor changes in neuropsy chiatric disorders by positron emission tomography (PET) requires reliable quantitative methods, and accordingly a number of approaches have been used to quantify PET studies of several neurorecep tor systems: dopamine (Mintun et aI ., 1984; Farde et aI ., 1986 Farde et aI ., , 1989 Perlmutter et aI ., 1986 Perlmutter et aI ., , 1989 Wong et aI ., 1986a, b; Logan et aI ., 1987 ; Bahn et aI ., 1989b; Huang et aI ., 1989) , benzodiazepine (Pappata et aI., 1988; Persson et aI ., 1989) , and opi ate (Frost et aI ., 1989a) .
The localization and quantification of opiate re ceptors by PET began with the use of e lC]car-fe ntanil, a potent fl-selective opiate agonist (Frost et aI., 1985) . Subsequently, [llC] carfentanil was used to demonstrate increases in fl-opiate receptors in patients with temporal lobe epilepsy (Frost et aI., 1988) . A multicompartmental tracer kinetic model was used to quantify the binding of high specific activity (SA) [llC] carfentanil in the presence and ab sence of the competitive inhibitor naloxone in normal volunteers (Frost et at. , 1989a) . These high SA studies did not permit opiate receptor concen tration (Bmax) and ligand affinity (Kd) to be sepa rately estimated, but did provide regional k31k4 ra tios, where k31k4 = BmaxlKd is the binding potential (Mintun et aI., 1984) . If a radioligand is adminis tered at both high (low receptor occupancy) and low (high receptor occupancy) SA, tracer kinetic com partmental modeling can yield separate estimates of Bmax and Kd (Huang et aI. , 1986) . However, a paired study approach cannot be carried out in hu man subjects with all ligands since many, such as [llC] carfentanil, elicit significant pharmacological effects at the high mass doses needed for low SA studies.
Diprenorphine is an opiate ligand that has two pharmacological properties that differ from those of carfentaniI. First, diprenorphine has similar high af finity for fl-, 0-, and K-opiate receptors in vitro (Chang et aI., 1981; Richards and Sadee , 1985) . Sec ond , in many pharmacological assays, diprenor phine acts as an antagonist (Blane and Dugdall, 1968) , although human studies at higher doses have demonstrated pharmacological effects that are con sistent with weak partial agonist properties (Reckett and Colman , 1975) . The lack of significant agonist activity permits the administration of a higher mass of diprenorphine without causing pharmacological side-effects and thus makes PET studies at low SA possible. [llC] Diprenorphine PET studies were ini tially performed using diprenorphine labeled with carbon-II in the cyclopropyl methyl group (Jones et aI., 1988) . Diprenorphine has also been labeled with carbon-ll in the 6-0-methyl position (Lever et at. , 1987) . PET studies have demonstrated that the dis tribution of [llC] diprenorphine in the human brain differs from that of e lC]carfentanil in a manner that is consistent with the respective subtype selectivity of the two ligands (Frost et aI. , 1989b) .
In this study, non-steady-state compartmental modeling and nonlinear least-squares curve fitting were used to analyze paired high and low SA [llC] diprenorphine PET studies performed in the same individual to obtain in vivo estimates of Bmax and Kd. Different compartmental models and fitting strategies were compared statistically to establish the most reliable method of parameter estimation.
METHODS

Data acquisition
PET studies. Six healthy men (aged 23-36 years), re cruited by advertisement, gave informed consent to par ticipate in the study. None of these subjects had a medical history of psychiatric or neurological disease or drug abuse. None were taking medications at the time of the study.
PET data were acquired on a NeuroECAT PET scan ner operating in the high resolution mode (Hoffman et aI. , 1983) . This scanner simultaneously acquires three images 32 mm apart. Fourteen scan sets, acquired for increasing time intervals (to compensate for radioactive decay), were obtained (Frost et aI. , 1989a) . Images were smoothed to a final image resolution of 14.5 mm. After correction for decay and attenuation (by a calculated method), regions of interest were drawn subjectively us ing PET images that were generated by summing data from 50 to 90 min post injection to improve anatomic detail. Activities in homologous left and right regions were averaged. Decay-corrected blood and brain time activity curves were then converted into units of concen tration (nM) using the SA of the tracer at the time of injection and calibration factors as previously described (Frost et aI. , 1989a) .
Other aspects of the acquisition procedure are similar to those that have previously been described (Frost et aI. , 1988 (Frost et aI. , , 1989a . A thermoplastic mask was molded to each subject's face. This mask facilitated repositioning be tween the various phases of the study and served to im mobilize the head. The planes of interest were identified prior to the PET study using x-ray computed tomography rllC]Diprenorphine was synthesized as described pre viously (Lever et aI. , 1987 ) using e IC]methyliodide, pre pared from high SA [llC]carbon dioxide produced with a Scanditronix RNP-16 biomedical cyclotron, and the ap propriate nor-methyl precursor. The radiochemical syn thesis yielded [II C]diprenorphine, labeled in the 6-O-methyl group, which was determined to be radiochem ically pure (>98%), sterile, and pyrogen-free. A sample of nonradioacti ve nor-( cyclopropylmethyl)diprenorphine was prepared using a modified version of the published procedure (Bentley and Hardy, 1967) .
Each of the six subjects was studied a total of two or three times in a single day with at least 2. 5 h separating the injection of rllC]diprenorphine in each study. High SA [llC]diprenorphine (mean SA: 2,611 Ci/mmol at the time of injection; range: 769-5,920 Ci/mmol) was admin istered in the first study. Five subjects successively re ceived low SA [IIC]diprenorphine (mean SA: 44 Ci/ mmol; range: 27-80 Ci/mmol) during the second study. Two of the subjects then participated in a third study. These subjects were intravenously pretreated with the opiate antagonist naloxone (1 and 1.5 mg/kg, respec tively) to inhibit opiate receptor binding. Naloxone was administered 15 min before the administration of the high SA rIIC]diprenorphine. Approximately 20 mCi of p lC]diprenorphine was administered in each phase of the protocol, regardless of SA.
Analysis of blood radioactivity. All blood samples were collected from a radial artery catheter. The time course of radioactivity in the plasma was determined from 40 blood samples (2-3 ml) that were collected throughout the 90-min PET study. Approximately 20 samples were obtained during the first 2 min following tracer injection and the remaining 20 samples were collected at increasing time intervals for the duration of the study. Samples were cen trifuged at 2,000 g for 5 min. The radioactivity concen trations in the plasma aliquots (500 fLl) were determined in a gamma counter.
Arterial blood samples were also collected to determine the fraction of the total plasma activity corresponding to unchanged [IIC]diprenorphine. These blood samples were obtained at 2, 5, 10, 15, 30, 45, 60, and 90 min post injection. Plasma activity was isolated for HPLC analysis following a procedure previously described (Frost et aI., 1989a) . Briefly, plasma samples were passed through ac tivated C I 8 reverse-phase Sep-Paks (Waters Associates). The Sep-Paks were then washed with 10 ml of H20 buff ered with 0. 1 N ammonium formate. Finally, the radio activity was eluted from the Sep-Paks by 2 ml of metha nol. At each step, the radioactivity concentrations in the eluant and the Sep-Pak cartridges were measured to de termine the final extraction efficiency of this procedure. In vitro control studies, in which [ ll C]diprenorphine was added directly to the blood, indicated that �95% of the plasma activity is recovered as unchanged e IC]di prenorphine at the end of this procedure.
Following filtration through an Acro LC 13 filter (Gel man Sciences), the radioactivity extracted from the plasma (methanol eluant) was diluted with O. I N ammo- nium formate buffer to a final concentration ratio of 75% methanoll25% buffer and applied to a C I 8 reverse-phase analytical column (Waters Associates) eluted with a mo bile phase of 75% methanoIl25% water buffered with 0. 1 N ammonium formate at a flow rate of 2 mllmin. Under these conditions, the retention time for [ II C]di_ prenorphine is �6 min. The HPLC system is equipped with two opposed 5-in NaI (TO detectors and a strip chart recorder. Each radioactive peak was automatically inte grated and later decay corrected back to the time of sam ple injection onto the column. The percentage of total activity corresponding to unmetabolized [llC]diprenor phine was then calculated for each time point.
Plasma protein binding. To determine the fraction of C IC]diprenorphine bound to plasma proteins, 5 ml of ar terial blood was collected in a heparinized syringe and centrifuged for 3-4 min at 10,000 g. Ten microcuries of [IIC]diprenorphine was then added to a I-ml plasma sam ple. The same amount of [ l lC]diprenorphine was also added to I ml of 50 mM Tris buffer (pH 7.4 at room temperature). In this control medium, all of the elC]diprenorphine in solution is assumed to be free. AI iquots (400 fLl) of each solution were pipetted into Cen trifree micropartition system units (Ami con) in duplicate. The Centrifree units were centrifuged for 20 min at 1,500 rpm in a fixed angle (35°) rotor centrifuge as recom mended by the manufacturer. After centrifugation, the radioactivity concentrations in 50 fLl of the ultrafil-trate and 50 fLl of the original sample (plasma or buffer) were measured in a gamma counter. The ratio between the counts in the ultrafiltrate and the counts in the plasma sample (X) represents the free fraction of [IIC]di_ prenorphine in plasma. This free fraction could be under estimated owing to the adsorption of free e I C]di prenorphine onto the components of the partition system. To account for this nonspecific binding, the ratio of the radioactivity in the ultrafiltrate from the buffer to that in the buffer solution (Y) was also calculated. The average magnitude of this nonspecific binding correction was 8%.
The free fraction of [IIC]diprenorphine in the plasma (/1) was calculated as I I = (X/Y) * w, where w = 0.94 ml water/ml plasma (Altman, 1961) .
Brain metaholite analysis. The chemical identification of the radioactivity detected in the brain following the administration of e IC]diprenorphine was carried out in mice. Male ICR mice (Charles River) were injected with -1 mCi of [ ll Cjdiprenorphine and killed by decapitation at 1, 30, and 45 min postinjection. The brain was rapidly removed and homogenized with a Polytron (Brinckmann) in 10 ml of ice-cold methanol. One hundred microliters of a 200 fLM solution of unlabeled diprenorphine was added to the homogenate. The solution was mixed and centri fuged at 20,000 g for 10 min in a Sorvall RC5C centrifuge (Dupont). The pellet and the supernatant were separated and the respective radioactivity concentrations deter mined using a gamma counter. Using this procedure, >90% of the radioactivity was extracted from the brain.
A mixture of 0.5 ml of water buffered with 0.1 N ammo nium formate and 1.5 ml of supernatant was then passed through an Acro LC 13 filter and analyzed by HPLC us ing the same conditions as described for the plasma sam ples.
Data analysis
A three-compartment kinetic model, similar to the one used to quantify [IIC]carfentanil binding (Frost et aI., 1989a) , was applied to the kinetics of ['IC]diprenorphine in mUltiple brain regions. The model consists of a vascu lar compartment (C I ), a brain tissue compartment corre sponding to free and nonspecifically bound ligand in the extracellular space (Cl), and a brain tissue compartment corresponding to specifically bound tracer (e3) (Fig. 2) .
Four kinetic parameters describe the transfer of the tracer between the compartments (K I , k2, k�, and k4). These parameters are varied to obtain the optimal model fit to
Representation of the three-compartment model used to analyze the kinetics of C 1 Cjdiprenorphine in the brain. C1 is the capillary plasma concentration. C2 and C3 are the concentrations of tracer in the brain tissue compart ments, with C2 the concentration of tracer in the extracellular space free and nonspecifica"y bound and C3 the concentra tion of ligand specifically bound to receptors. Since the con tribution of C 1 to the total positron emission tomography signal is assumed to be negligible, the model function (CTl is assumed to be equal to the sum of C2 and C3. The parameters K1-k4 are kinetic parameters for transport of the tracer be tween the compartments.
the PET data and are estimated using nonlinear least squares curve fitting.
Model equations. The model solution [e T (t)] was com puted as
(I)
The vascular compartment (e I ) was not kinetically modeled or directly measured. Using the measured total blood and brain concentration curves and a blood volume of 0.05 ml/g tissue, it can be calculated that blood radio activity contributes to only 5% of the brain radioactivity at early time points (3 min post injection) and to <0.5% at late time points.
The pair of differential equations that describe the changes in the compartmental concentrations (nM) with time is
The transport between the vascular compartment (e l ) and the extracellular compartment (e2) is assumed to oc cur by passive diffusion and to be bidirectional. The pa rameter K I (mllg-min) combines flow and transport from blood into brain. It is defined as (4) where F is the rate of plasma flow per ml of brain tissue (mUmin-ml), PS is the brain permeability-surface area product for plasma (mUmin-ml), andi l is the free fraction of tracer in the plasma (Frey et aI., 1985 (Frey et aI., , 1986 . The k2
parameter (min -I) describes the transport of the tracer out of the extracellular space (C2) and across the blood brain barrier. This parameter contains the factor 12' which is the free fraction of tracer in the extracellular space and therefore able to move from one compartment to another. Free and nonspecifically bound ligand in compartments 1 and 2 is assumed to be in rapid equilibrium.
The kinetic parameters that describe the binding to and dissociation from receptors are k; and k4, respectively. The kinetic parameter k; is defined as follows:
where kon is the bimolecular association rate constant (nM-Imin -I) and Bmax is the total concentration of re ceptors available for binding (nM). It can be seen from Eq. 5 that the kinetic parameter k; is sensitive to the concentration of receptors occupied by the radiotracer. At high SA, the concentration of bound ligand is neg ligible compared with the concentration of unoccupied receptors [Bmax "9 e3(t)] and C3(t) can be neglected in Eq. 5. The kinetic parameter k; then becomes k3, a pseudofirst-order rate constant defined as -
Under these conditions of low receptor occupancy, the equations describing the changes of the compartmental concentrations with time are linear first-order differential equations. These equations contain constant coefficients and are solved using Laplace transforms. The solution for this set of equations has been described in detail else where (Huang et al., 1980; Frost et al., 1989a) .
At low SA, the concentration of bound tracer [C3(t)] becomes significant compared to B m a x and the operational equations become
and which can also be expressed as
The product C3(t) C2(t) is nonlinear and the method used to solve the equations previously described for the high SA situation is no longer appropriate. Equations 7 and 8, however, can be solved by numerical integration.
A fourth-order Runge-Kutta method ( 
and therefore, the equilibrium dissociation is (12) and the association constant can be calculated as follows:
The model solution was compared to the observed PET data to obtain optimal estimates of the kinetic parame ters. This was performed by a nonlinear least-squares
minimization procedure (Marquardt, 1963) . The uncer tainty in the ith parameter estimate (Ei) was computed as
where dl is degrees of freedom and Ei is the variance associated with the ith model parameter and is the ith diagonal element of the covariance matrix (Carson, 1986) .
The coefficient of variation (%) of the ith model parame ter was also computed: (E/parameter estimate;) * 100.
Eight different fitting strategies were used to analyze the data. The first strategy involved the use of a two compartment model. For this model, it was assumed that no specific binding occurs and C3(t) is negligible. The remaining fitting strategies used a three-or four-com partment model and will be referred to as methods A-G ( Table 1 ).
The linear model equations were used in methods A-C. Method A was a three-compartment model fit when all parameters (KI, k2' k3' and k4) were allowed to vary in dependently. Method B was also a three-compartment fit, but K/k2 was fixed to the value obtained in the occipital region while KI, k3, and k4 were free to vary. Method C refers to a four-compartment model, similar to that used for [ I lC]carfentanil (Frost et aI., 1989a) . In method C, k5 and k6 (the parameters connecting C2 to the fourth com partment, C4) were, respectively, fixed to the k3 and k4 values obtained for the third compartment in the nalox one studies.
The nonlinear solution of the three-compartment model was used in methods D-G. All parameters (K I , k2' k3' k4' and k+) were allowed to float for method D. In method E, the K J lk2 ratio was constrained to the value obtained from the low SA occipital fit and KI, k3, k4' and k+ were var ied. In method F, the k3 value was constrained to that obtained from the high SA fit for the same region while KI, k2' k4' and k+ varied. Method G used both the K/k2 constraint and the high SA k3 constraint while K1, k4' and k + were free to vary.
Comparisons between fits and fitting strategies were conducted using both a paired Student t test and a mod ification of the Akaike information criterion (Akaike, 1974) , redefined as AIC = -n In (SSQ) -2p, where n is the number of data points, SSQ is the sum of squared errors, and p is the number of parameters (Frost et aI., 1989a) . The AIC values for the high SA fits are positive while those for the low SA fits may be negative. This is because the low SA SSQ values are much larger than the SSQ values for the high SA case. A larger AIC value is indicative of a better fit. In all instances, means of data are presented with their standard deviations. The major assumptions of this mathematical model were as follows: (a) The measured arterial plasma con centration (Cp) is equal to the average capillary concen tration (C I); (b) the contribution of the blood pool to the observed PET counts is negligible; (c) high SA receptor occupancy is negligible « 10%); (d) the radioactivity de tected in the brain is present only as [llC]diprenorphine;
(e) nonspecifically bound P IC]diprenorphine in plasma and in brain is in rapid equilibrium with the free fraction; and (0 [llC]diprenorphine has a similar affinity for each opiate receptor subtype in vivo.
Two additional assumptions were made when applying certain fitting strategies: (a) The volume of distribution of free and nonspecific binding is similar in all brain regions for a given study, and (b) k3 (Eq. 6) is the same for high and low SA experiments in a given individual.
RESULTS
The average mass-dose of diprenorphine admin istered in the high SA studies was 0.05 J.1g/kg. No pharmacological effects were reported by any of the subjects during these studies. Similarly, no side effects were observed fo llowing the administration of 1 and 1.5 mg/kg of naloxone. On the other hand, during the low SA studies, all subjects experienced mild opioid-like effects (e .g., slight sedation). These sensations were reported as neither pleasant nor un pleasant and were transient. No cardiovascular or respiratory side-effects were observed. The average mass-dose of diprenorphine administered during the low SA studies was 2.67 ± 0. 16 J.1g/kg (correspond ing to an SA of 34 ± 6 Ci/mmol) for the four subjects whose data were analyzed by the models. A fifth subject received a lower mass-dose of 1.38 J.1g/kg (SA: 80 Ci/mmol) .
[ ll C]Diprenorphine metabolites
The final recovery of radioactivity from the arte rial samples was less than that recovered from the in vitro control samples (containing only e IC]di prenorphine). In addition, there was a decrease with time in the final recovery (from a mean of 87% with the 2-min samples to a mean of 62% with the 90-min samples). This progressive decrease in the extraction efficiency coincided with the detection of labeled metabolites by HPLC. Therefore , it was as sumed that the increasing radioactive fr action not retained on the Sep-Pak during the extraction pro cedure corresponded to labeled polar metabolites and not to [llC] diprenorphine. HPLC results were corrected using the actual percentage of the plasma activity not retained in addition to that not retained from the control samples. The largest correction was needed for the 90-min samples where the HPLC underestimated the percentage of labeled metabolites by 13%.
The kinetics of unmetabolized e IC]diprenor phine, expressed as a fraction of the total plasma activity and averaged for the six subjects, is pre sented in Fig. 3 . These are averages of the high and low SA results, which did not differ significantly. Soon after the intravenous administration of e IC]diprenorphine, IIC-Iabeled metabolites appear and with time they constitute an increasing fraction of the total plasma radioactivity. The reduction in the unchanged fr action over time can be decom posed into a fa st (t1/2 = 15 min) and a slow (1112 = 120 min) component. The HPLC chromatograms (Fig.  4A) show the presence of one broad metabolite(s) peak (one major and at least one minor labeled me tabolite). Based upon the retention profile , under reverse-phase HPLC conditions, these substances are more polar than e IC]diprenorphine. By con trast, the HPLC analysis of the activity extracted fr om the mouse brain following the administration of [llC]diprenorphine (sampled 45 min post injec tion) revealed the presence of only one peak, cor responding to unmetabolized [ llC]diprenorphine (Fig. 4B ). This demonstrates that radiolabeled me tabolites of [II C]diprenorphine do not accumulate in mouse brain. A B ± 0.03. There were no differences between the I, measured during the high and low SA studies. This average I I was equivalent to the I, value obtained during a naloxone study if, determined for one nal oxone study) and this value of I I was used for the calculation of 12 ' Regional distribution of [IIC ]diprenorphine: high SA, low SA, and naloxone studies
The distribution of radioactivity in the brain fol lowing [IIC]diprenorphine administration for the high SA (5 ,920 Ci/mmol), low SA (4 1 Ci/mmol) , and high SA/naloxone pretreatment studies of one of the volunteers is shown in Fig. 1 . At high SA, a pref erential accumulation of the tracer is observed in areas known to contain a high concentration of opi ate receptors (e.g. , thalamus, basal ganglia, and cortex). In contrast , there is less accumulation of [ llC]diprenorphine in the occipital cortex, an area known to contain a low concentration of opiate re ceptors (Kuhar et aI., 1973 ; Pfeiffer et aI., 1982; Frost et al ., 1985) .
Tracer uptake is reduced in all regions when low SA [ llC]diprenorphine is administered, owing to partial saturation of receptors. Following naloxone 
Model fits
Naloxone studies. The linear solutions of the two-and three-compartment models were used to fit the data obtained in 16 brain regions during the naloxone studies. Typical examples of fits to the occipital cortex data are shown in Fig. 5 . The two compartment model underestimated brain concen trations for times greater than 30 min post injection in all brain regions. The fits were always improved when a three-compartment model was used to fit the data. This improvement is reflected in an in crease in the AIC value from 71 ± 8 to 108 ± 8 (p < 0.0009) for the two-and three-compartment models, respectively. The K I /k2 ratio , averaged fr om the 16 regions (two subjects) , was 1.1 ± 0.2 (three com partments) . This value was used to calculate 12, the t'C}DIPRENORPHINE BINDING TO OPIATE RECEPTORS
FIG. 5. Two-and three-compartment model fits to the ob served data in the occipital cortex in a naloxone study. The two-compartment model fit underestimates the data for times greater than 30-40 min. The fit is improved when a three-compartment model is used. Similar results were ob tained in all regions for the naloxone studies.
fr ee fr action of tracer in the extracellular space (Eq. 11). Using the measured! 1 value of 0.30, the calcu lated value of !2 was 0.3. In these two naloxone studies, the mean percentage of regional variation fr om the respective mean K/k2 ratio was 6 and 11%, indicating relative uniformity of the ratio across re gions. In addition, Patlak plots (Patlak et aI., 1986) of the naloxone data support the steady-state as sumption of Eq. 11.
Occipital cortex. The occipital cortex is a region with low levels of opiate receptors (Fig . 1) . This region has been used previously to estimate the nonspecific binding of e IC]carfentanil (Frost et aI ., 1985 (Frost et aI ., , 1989a . Inspection of the [IIC]diprenorphine time-activity curves, however, revealed a small but reproducible reduction in the e l C]diprenorphine uptake both at lower SA and after naloxone pre treatment compared to the high SA study (Frost et aI ., 1989b) . It is therefore likely that some degree of specific binding is taking place in the occipital cor tex with e IC]diprenQrphine. However, since the magnitude of the specific binding is so much lower than in any other region, the occipital cortex was analyzed separately and differently than were re ceptor-rich regions.
The linear solution of the three-compartment model always gave better fi ts than the two compartment model, for both the high and the low SA studies. The AIC increased significantly fr om 66 ± 20 to 95 ± 17 (p = 0.00 1, high SA) and fr om -50 ± 7 to -20 ± 12 (p = 0.01 , low SA) when a three rather than two-compartment model was used. The Kllk2 ratio decreased fr om 1.5 ± 0.2 in the high SA studies to 0.9 ± 0.5 in the low SA studies, owing to a significant increase in k2 (p = 0.005), without a change in K I (p = 0.9 , NS). The average K/k2 ratio fr om the low SA studies (0.9 ± 0.5) was close to the average K/k2 ratio fr om the naloxone studies 0. 1 ± 0.2). The high SA occipital cortex fits were not signif icantly improved by the use of a metabolite corrected plasma curve (p = 0.36). The mean K/kz ratio , however, significantly increased fr om 1.0 ± 0.4 to 1.4 ± 0.2 (p = 0.04) with the use of a metab olite-corrected plasma curve.
The low SA studies were also fitted using method F. The estimated k + value was always very low «0.005 min � I ), associated with large errors (3 1-220%) , and in one instance was negative. For that reason, the linear solution was used to fit the occipital cortex data. The AIC values were similar using either the linear (L) or the nonlinear (NL) solution [AICL(method A): -20 ± 12; AICNL(method F): -19 ± 9; p = 0.93 , NS]. The mean K/k2 ratio was equivalent for both methods (L: 0.9 ± 0.5 ; NL: 0.9 ± 0.5 ; p = 0.5 , NS).
Receptor-rich regions. high SA. Various strate gies were tested on the time-concentration curves obtained in three receptor-containing regions (thal amus, cingulate cortex, and frontal cortex) from the high SA studies (n = 5). Method A provided good fits to the observed data, but large percentage er rors were associated with the parameters, particu larly k2 and k3 (45.5 ± 23.0 and 47.7 ± 17.6%, re spectively). Furthermore, the coefficient of varia tion of the mean of these parameter estimates was large (ranging from 33 to 64%). The mean K/k2 ratio determined using method A for these three recep tor-rich regions 0.5 ± 0.5) was equivalent to the mean K/k2 ratio determined for the occipital cortex from the high SA studies (1.5 ± 0.2).
Method B did not improve the AIC value as com pared with method A (AICA: 88 ± 19; AICB: 88 ± 20; p = 0.75, NS), but did significantly lower the percentage error associated with k3 (15.1 ± 4.7%) as compared with method A (47.7 ± 17.6% ; p < 0.0009).
In four of five instances, method C did not pro vide adequate fits to the occipital cortex data be cause of matrix singularity. In receptor-rich re gions , the estimates for k3 and k4 generally had large errors (>50%).
Given these results, method B was chosen as the most desirable way to fit the high SA time concentration curves obtained in seven receptor rich brain regions. An example of a fit to the thal amus data from one volunteer is shown in Fig. 6 . The mean values (±SD) of the various kinetic pa rameters are presented in Table 2 . The mean value (±SD) of the k31k4 ratio varied fr om 8.6 ± 1.6 in the
FIG. 6. Three-compartment fit to high specific activity thala mus data. The linear set of equations for the three compartment model was used to fit the data. The K1/k2 ratio was fixed to the value obtained in the occipital cortex of the same study (method 8).
thalamus to 3.7 ± 0.7 in the cerebellum. A signifi cant linear relationship was fo und between the mean kik4 ratio and the mean percentage injected dose (% ID) detected fr om 75 to 95 min post injec tion (% ID = 1.4 + 0.41 k31k4; r = 0.96, P < 0.0009, five subjects, nine regions). The use of the linearized model equations for the high SA data was further justified by comparing these results with fits obtained using the nonlinear model. When the high SA data were fit with the nonlinear model (including k+) , the AIC values were essentially identical (AIC L = 87 ± 24 ; AIC NL: 86 ± 20) , but the errors associated with the param eters were higher. In particular, the value of k + was undetermined (errors > 100%). The lack of an im proved fit to the data with the nonlinear model is consistent with negligible receptor occupancy in the high SA studies.
Receptor-rich regions, low SA. At low SA, par tial saturation of the receptors occurs and accounts for the overall reduction in tracer uptake and the change in the shape of the brain curves (Fig. 7) .
Various strategies of analysis were tested on the low SA data collected fr om three receptor-rich re gions (thalamus, cingulate , and fr ontal cortex). Four subjects were included in the analysis (SA range: 27-41 Ci/mmol) . A fifth subject (not included in the present analysis) received 80 Ci/mmol of el C]diprenorphine for the low SA study. Adequate fits could not be obtained for this study and the estimated parameters were associated with large er rors , most likely due to an insuffi cient occupancy of receptors .
Methods D and E could be applied to a single low SA study , for the case where a high SA study was not available. However, with method D poor fits were obtained. Furthermore , two of four estimates of k + were negative and k3 was always accompa nied by large errors (> 100%) . Therefore, as with the high SA studies, it was necessary to use some a priori information to constrain the fits . The next fitting strategy used was method E, which involved fixing the Kllk2 ratio . In one subject, fits could not be obtained owing to matrix singularity. For the remaining three subjects, the estimated parameters were highly variable and associated with large er rors .
As described in Methods, k3 is assumed to remain constant in a given individual during the high and the low SA studies. Therefore , the k3 estimates ob tained fr om the high SA fits were used as a priori information for the low SA fits using method F. This method provided close fi ts to the observed data with acceptable parameter errors. The mean percentage error in k + was 20.2 ± 7.2%. It is note worthy that the mean K I I k2 ratio obtained by method F (0.9 ± 0.6) was equivalent to the mean K/k2 ratio calculated fr om the fits in the occipital cortex at low SA (0.9 ± 0.5) (method A) . The lower SA corresponds to a higher brain concentration. Partial receptor saturation accounts for the change in the shape of the curve. The best fit to the data was obtained using the nonlinear set of model equations for the three-compartment model, fixing K 1 /k2 to the value de termined in the occipital cortex of the same study and k3 to the value determined in the same region during the high SA study (method G).
Finally, method G was applied to fit the data. An example of a thalamic fit by this method is pre sented in Fig. 7 . The AIC values using method G were similar to those obtained with method F (AICF: -25 ± 13; AICG: -27 ± 14; p = 0.055, NS). The errors associated with k4 and k+ were significantly lower using method G [k4(F): 50.6 ± 48.6% , kiG): 25.6 ± 11.9% , p = 0.05 ; k+(F): 20.2 ± 7.2% , k+(G): 11.8 ± 4.8%, P < 0.0009).
The effect of the method of analysis on the esti mate of the koJ2 product, in the low SA studies, is illustrated in Fig. 8 . The results provided by meth ods E and G are compared. Data are from only three subjects since method E resulted in matrix singularity for one subject. The intersubject vari ability in the koJ2 estimates, as well as the error associated with this parameter, was much larger when k3 was allowed to float (method E) than when the high SA k3 was used to constrai n the fits (method G).
Method G provided the best fits to the low SA studies and was used to analyze a total of seven brain regions for each subject. The estimated ki netic parameters and the calculated value of 12 were used to determine the regional concentration of available receptors (Bmax), the binding affinity (Kd), and the association constant (kon) (Eqs. 9, 12, and 13, respectively). Furthermore , as koJ2 could not be estimated accurately in the occipital cortex (probably owing to the low number of receptors), a value of koJ2 corresponding to the mean koJ2 of the seven other regions was assigned to the occipital cortex. The results are presented in Table 3 . The concentration of available receptors (Bmax) is high est in the cingulate (20.5 nM) , caudate (19.9 nM), and thalamus (18.6 nM) and lowest in the cerebel lum (6.8 nM) and in the occipital cortex (2.3 nM).
The average Kd obtained for eight brain regions (in cluding occipital) was 0.85 ± 0. 17. Significant linear relationships were fo und between the mean regional Bmax value and the mean kik4 ratio calculated from the high SA fits (Bmax = 0.3 1 + 2.42 k31k4 ; r = 0.95 , p < 0.0009) and between the mean Bmax value and the mean percentage injected dose detected in the brain 75-95 min post injection (% ID = 1.5 + 0. 16 Bmax; r = 0.91 , P = 0.001).
The parameters estimated for the thalamus region using method B (high SA studies) and method G (low SA studies) were used to simulate C3(t). The calculated Bmax value was then used to determine the percentage receptor occupancy, which is ex pressed as (C3IBmax) * 100% . During the high SA studies, the maximum receptor occupancy achieved was 1.4 ± 0.4% for four subjects; the occupancy was higher in the subject who received 769 Ci/mmol of [ llC]diprenorphine (6.6%). The average low SA receptor occupancy varied from 53.2 ± 10.2 (during the last 30 min of the studies) to a maximum of 73.5 ± 8.0% near the beginning of the studies for four subjects. The receptor occupancy was much lower (�40%) fo r the fifth subject who received 80 Ci/mmol [IIC]diprenorphine.
DISCUSSION
The results of this study demonstrate that reliable estimates of brain receptor concentration and affin ity can be obtained from paired dynamic PET scans , provided that both low and high receptor oc cupancies are achieved. Using [II C]diprenorphine , at high and low SAs, and a non-steady-state com partmental model , we have estimated human brain opiate receptor concentration and affinity in vivo.
Several methods of analysis have been previously used to quantify PET neuroreceptor binding stud ies. These techniques can be divided into equilib rium (Farde et aI., 1986; Pappata et aI., 1988; Pers son et aI. , 1989) , and nonequilibrium (Mintun et aI., 1984; Perlmutter et aI., 1986 Perlmutter et aI., , 1989 Wong et aI., 1986a, b; Logan et aI. , 1987 ; Bahn et aI. , 1 989b; Frost et aI. , 1989a; Huang et aI. , 1989) methods. The advantages and limitations of these techniques have been reviewed in detail elsewhere (Huang et aI., 1986; Zeeberg et aI., 1988) .
Many PET ligands, including [llC]diprenorphine (Frost et aI., 1989b) , do not reach equilibrium dur- ing the time frame of the PET study (90 min) and require nonequilibrium methods of quantification. Two types of kinetic methods are currently used to analyze PET data. The first type is an adaptation of the graphical method (Patlak and Blasberg , 1985) . This method has been applied to [IIC]N-meth ylspiperone to quantify dopamine D2 receptors as suming steady-state conditions (Wong et aI., 1986a,b) . The second type is a non-steady-state method that is more generally applicable and uses nonlinear regression techniques to estimate the ki netic parameters. The non-steady-state approach has been used to quantify the irreversible binding of 18 P-spiperone (Mintun et aI., 1984; Perlmutter et aI., 1986 Perlmutter et aI., , 1989 Logan et aI. , 1987) and e S p]fluoro ethylspiperone (Bahn et aI. , 1989b; Huang et aI. , 1989) 8. Effect of the method used to analyze the data from the low specific activity (SA) studies on the estimate of the product k onf2 and its error (n = 3 subjects). Fits were ob tained using the time-concentration curves in three regions from the low SA studies. The kinetic parameter k3 was either allowed to float (method E; 0) or fixed to the value ob tained in the same region during the high SA study (method G; .) . The variability in k3 and the error associated with that parameter are much larger when k3 is allowed to vary inde pendently.
been performed at low receptor occupancy. These single injection studies did not allow the receptor concentration and affinity to be separately esti mated , although this is theoretically possible using a high receptor occupancy (low SA) single injection study. Several of the model assumptions listed earlier are common to many kinetic models used to ana lyze PET data. Pirst, if the blood flow is high and extraction is small, C1 can be approximated by the plasma concentration (Cp)' In our studies, using a typical Kl value of 0.108 ml/g min and a flow value of 0.56 ml/g min, the calculated extraction fraction is <20%. In fact, previous studies of the dopamine system have supported the validity of this assump tion (Logan et aI., 1987; Bahn et aI., 1989b) . Sec ond, we did not measure regional blood volume and assume that the blood pool activity does not con tribute significantly to the PET activity, particularly at the later times when receptor binding predomi nates. Previous simulation studies, using [ llC]- carfentanil, demonstrated that the vascular contri bution to the total PET brain signal was not signif icant (Frost et al., 1989a) , but this issue will be directly addressed fo r ["C] diprenorphine in the fu ture . The third model assumption was that the high SA receptor occupancy was negligible « 10%). The high SA study must result in low receptor occu pancy « 1 0%) since k; is sensitive to receptor oc cupancy. If the linear set of equations is used, and the concentration of bound ligand is not low com pared to Bmax, k; will not be equivalent to k3 ' and k3 will be underestimated. In all of our high SA stud ies, including the volunteer with the lowest high SA dose (769 Ci/mmol), the peak receptor occupancy was well under 10%. Fourth, it was assumed that the radioactivity de tected in the brain represented only unmetabolized [I 1 C]diprenorphine. Our experiments in mice indi cated that for times up to 45 min post injection, the activity detected in the brain was unchanged [I 1 C]diprenorphine. This supports our assumption that, in humans, brain activity corresponds only to [I IC]diprenorphine. The correction of the input fu nction for the presence of labeled metabolites was performed in each of the human studies. In contrast to the tracer kinetic modeling studies using [I 1 C] carfentanil, metabolite correction did not result in a signifi cant improvement in the fits fo r e IC]-diprenorphine. In the occipital region, the use of an uncorrected input function resulted in a 34% under estimation of the volume of distribution (Vd)' This situation can be expected when metabolites do not cross the blood-brain barrier, since the equilibrium volume of distribution is equivalent to the ratio C2/C I • This would fu rther support the assumption that all activity in the brain was unchanged [I 1C]diprenorphine. The identity of the labeled me tabolites extracted fr om plasma and detected by HPLC is not known with certainty. Buprenorphine, a structural congener of diprenorphine, is metabo lized in humans to nor-(cyclopropyl)buprenorphine (Cone et aI . , 1984) . The retention time of nor (cyclopropylmethyl)diprenorphine on the HPLC column is identical to the retention time of the ma jor peak corresponding to polar IIC-metabolites (data not shown) , which suggests that N-dealkyl ation of [ llC]diprenorphine occurs in humans.
Fifth, given the rapid rates of association and dis sociation for nonspecific ligand interactions with plasma proteins, it is likely that the nonspecific fraction is in rapid equilibrium with the free fraction in the brain as well. Sixth, the assumption that [I 1C]diprenorphine binds equally to the opiate re ceptor subtypes is supported by in vitro studies (Chang et aI ., 1981; Richards and Sadee, 1985) and by the observation that the data could be fit well assuming a single value of kon and k Off '
A key element of this work was to determine an optimal fitting strategy that would produce the most reliable fi ts to the experimental data. This was achieved when the curve fits of receptor-rich re gions were constrained by holding one or more of the kinetic parameters constant. The results from this and other studies (Carson et al ., 1989) confirm that the simultaneous estimation of fo ur indepen dent parameters is often difficult and may lead to large uncertainties in the parameter estimates. The best fi ts with the smallest parameter errors were obtained in both the high and the low SA studies when only three parameters were fi t simulta neously. It appears to be legitimate to use two types of a priori information to constrain the fits.
First, the Kllk2 ratios obtained from the high or low SA occipital fit were used as constraints in many of the fitting methods. The naloxone-blocking studies indicated that the V d for free and nonspe cific binding (Kllk2; ) was uniform across regions. Furthermore , the mean K/k2 ratio obtained from curve fits in receptor containing regions, when K I and k2 were allowed to float, was close to the mean Kllk2 in the occipital cortex. Therefore , in a given study, the estimated value of the Vd fo und in a region with negligible specific binding could be used to constrain the fits in receptor-rich regions. Inspection of the time activity curves obtained in the occipital cortex and the compartmental modeling results indicated that a small degree of receptor binding does occur in the occipital cortex. However, when a naloxone study cannot be performed, the activity in the occipital cortex provides a satisfactory estimate of K/k2' since the level of specific binding is small.
To fu rther support this approach, we have per fo rmed simulation experiments to examine whether the KJlk2 ratio can be reliably estimated in the pres ence of a small amount of receptor binding. Occip ital curves were simulated (with the addition of noise) using fixed values for K I ' k2 ' and k4 while k3 was varied to obtain k31k4 ratios that ranged from 0 to 10. This resulted in curves that were similar in shape and data point scatter to those observed ex perimentally. These curves were then fit using a three-compartment model to determine the value of Ktfk2. The lower the value of k31k4' the better the fit value of K/k2 corresponded to the value used to generate the simulated occipital curves. Specifi cally, when kik4 was set to twice the best fit value in the occipital cortex, the estimated value of K/k2 in the simulation experiment was well within 5% of the true value .
The second type of fitting constraint was used in the low SA fits. In the low SA studies, the model equations required the estimation of fi ve parame ters. It is logical to fix k3 to the value fo und at high SA since this parameter, defined as the product korf2Bmax, is constant and does not change with re ceptor occupancy. The effe ct of fixing k3 was a re duction in the error associated with the k4 and k + estimates. Our results (Fig. 8 ) demonstrate that the information obtained during a high SA (low recep tor occupancy) study is needed to obtain acceptably low coefficients of variation in the parameter esti mates obtained from the low SA study.
The average (±SD) concentration of opiate re ceptors in the human brain measured in four normal subjects ranged from 2.3 ± 0.5 nM in the occipital cortex to 20.5 ± 7.3 nM in the cingulate cortex. The average Kd derived from the data was 0.85 ± 0. 17 nM and was fairly uniform across the eight brain regions analyzed. The only previous estimates of these binding constants have been obtained from in vitro experiments. Pfeiffe r et ai . (1982) fo und a maximal binding capacity of 14.8 nM and an appar ent dissociation constant of 0.22 nM (35°C) in the frontal cortex using eH]diprenorphine. Intere st ingly, our results are similar in magnitude to these in vitro values. This similarity is more likely to oc cur with diprenorphine than with an opiate agonist J Cereb Blood Flow Metab. Vol. 11. No.2. 1991 like carfentanil (Frost et aI ., 1989a; Titeler et aI ., 1989) . Unlike opiate agonists, the affinity of di prenorphine is minimally sensitive to the regulatory influence of sodium ions and endogenous guanylnu cleotides, which decrease the affinity of opiate ag onists in vitro (Childers and Smyder, 1980 ; Ku rowski et aI., 1982; Titeler et aI ., 1989) .
A close correspondence between in vitro and in vivo values does not constitute validation of the method since there are many reasons for in vivo and in vitro values to differ. A number of studies have reported differences between parameters deter mined in vivo and in vitro (Perry et aI ., 1980; Frost and Wagner, 1984; Bennett and Wooten, 1986; Perl mutter and Raichle , 1986) . If the ligand distribution is determined predominately by binding to recep tors , one would expect to find a correlation between the measured tracer concentrations and the esti mates of Bma x. A correlation was found between the values of Bmax in Table 3 and the percentage in jected dose within the corresponding region in the 75-to 95-min postinjection time interval (r = 0.91, p = 0.001). Furthermore , the rank order of the Bmax estimates is in general agreement with the regional distribution of opiate receptors determined in vitro (Pfeiffer et aI ., 1982; Cross et aI ., 1987) . Bmax is also closely related to the kik4 ratio determined from the high SA study. The observation of a significant re lationship between Bmax ' k31k4' and the percentage injected dose suggests the absence of a significant flow-transport limitation in the binding of e lC]di prenorphine to opiate receptors .
When the determination of Bmax is desired, it is important to achieve an appropriate degree of re ceptor occupancy for the low SA phase of the mea surement . It is likely that there exists an optimal receptor occupancy that, if achieved, will minimize the error associated with k + and Bmax' Inadequate receptor occupancy leads to large errors in k + , since the nonlinear terms are negligible. Excessive occupancy makes it difficult to accurately quantify specific receptor binding. Simulation experiments are underway in our group and have been per fo rmed by others (Bahn et aI ., 1989a; 10vkar et aI ., 1989) to determine the optimum degree of receptor saturation required for reliable parameter estima tion. In our low SA PET studies, the degree of re ceptor occupancy varied from 73% at the early times to 53% at the late time points. The subject who received 80 Ci/mmol e J C]diprenorphine had an occupancy that was lower (40%) . In this individual adequate estimates of k + could not be obtained.
The effect of varying the receptor occupancy on the model equations was investigated by fitting the same data with both the linear and the nonlinear models. At high SA, the AIC values were similar whether the linear or the nonlinear set of equations was used to fit the observed data, supporting the assumption of negligible receptor occupancy at high SA. By contrast, at low SA, the fits were signifi cantly better when the nonlinear set of equations was used (Table 4 ) . Furthermore , it is important to note that reliable estimates of kon (and low errors) were obtained only from the fits of the low SA data.
Although the results of this study suggest the gen eral applicability and reliability of our method, there are still unresolved issues. First , the volume of distribution for nonspecific binding decreased significantly between high and low SA studies (i . e. , the volume of distribution for the nonspecific bind ing decreased). This phenomenon has been ob served with other ligands in regions devoid of sig nificant specific binding, such as the cerebellum with 18F-spiperone (Logan et aI ., 1987) and in the occipital cortex with [llC]carfentanil (Fro st et aI ., 1989a) . In our study, the change was related to an increase in k2, without a concomitant increase in K I' The reason for this increase in kl is not known.
Second, fo llowing pretreatment with naloxone (a condition where all opiate receptors are expected to be blocked), a three-compartment model was nec essary to fit the observed data. This observation was also reported for several PET studies of the dopamine system (Logan et aI ., 1987; Bahn et aI ., 1989b; Farde et aI., 1989 ; Huang et aI ., 1989) . Sev eral explanations are possible. A small number of specific binding sites may have remained available for [11C]diprenorphine despite the high doses of nal oxone . In contrast to the mouse, labeled metabo lites may be present in the human brain during the time of the study. A more likely explanation is the existence of a small nonspecific binding compart ment that can be distinguished kinetically from C2 when there is no receptor binding. This compart ment would be small and should not affe ct k3 and k4 estimates in receptor-rich areas.
Three reports have recently appeared in the liter ature describing the use of high and low SA PET studies to quantify D2 dopamine receptor binding. Farde et al . (1989) used [llC] raclopride to estimate human putamen Bmax and Kd .
[18F]Fluoro ethylspiperone PET studies provided estimates of Bmax in monkey striatum (Bahn et aI ., 1989b; Huang et aI., 1989) . The general approach and model equa tions are similar in these investigations and in the present one , but there are some differences in the implementation of the model with respect to the curve-fitting techniques.
A feature common to these three approaches is the use of parameter constraints. In this work, the most reproducible estimates were obtained when K/kz from the occipital cortex and k3 from the high SA study were used as constraints. The initial puta men fit performed by Farde et aI . (1989) provided limits for the values of K I' k2, and k4 during the fitting process. Huang et al . (1989) and Bahn et aI . (1989b) constrained the k O frlkorf2 ratio to a value that was based on binding data from in vitro homog enate studies and an f2 value obtained from PET baboon studies. The advantages and limitations of using in vivo and in vitro data as parameter con straints in PET studies will be better identified in subsequent studies.
In summary , a three-compartment kinetic model was applied to paired high and low SA [ llC]di prenorphine PET studies and quantitative estimates of regional human opiate receptor concentration and ligand affinity were obtained . Although Bmax and Kd can theoretically be obtained from a single low SA study , our results suggest that the binding parameters are more reliably estimated from paired high and low SA studies. Parameter constraints based on individual in vivo PET data were required to achieve low coefficients of variation in the pa rameter estimates. This approach is general and versatile and can be applied to PET studies of other neuroreceptor systems.
